Investments

12 Months Ended

Jun. 30, 2024

Equity Method Investments and Joint Ventures [Abstract]

Equity investments by measurement category as of June 30, 2024 and June 30, 2023 were as follows (in thousands):


Measurement category	2024		2023
Fair value	$	12,026	$	12,423
Measurement alternative	73,739		68,748
Equity method	65,462		65,366
Total	$	151,227	$	146,537

The following table shows a reconciliation of the changes in our equity investments for the year ended June 30, 2024 (in thousands):


	Non-marketable securities		Marketable securities		Equity method investments		Total
Balance at the beginning of the period	$	68,748	$	12,423	$	65,366	$	146,537
Additions to investments	8,640		1,000		3,125		12,765
Observable price adjustments on non-marketable equity securities	2,315		—		—		2,315
Impairment of investments	(4,963)		—		—		(4,963)

Proceeds from exits of investments	(1,000)		—		—		(1,000)
Unrealized losses on marketable equity securities	—		(1,397)		—		(1,397)
Loss attributable to equity method investments	—		—		(1,848)		(1,848)

Foreign currency translation adjustments	(1)		—		(1,181)		(1,182)
Carrying value at the end of the period	$	73,739	$	12,026	$	65,462	$	151,227

The following table shows a reconciliation of the changes in our equity investments for the year ended June 30, 2023 (in thousands):


	Non-marketable securities		Marketable securities		Equity method investments		Total
Balance at the beginning of the period	$	39,290	$	9,167	$	9,918	$	58,375
Additions to investments (1)	21,738		4,991		62,733		89,462
Observable price adjustments on non-marketable equity securities	12,612		—		—		12,612
Impairment of investments	(4,892)		—		—		(4,892)
Realized gains on marketable and non-marketable equity securities	3,937		—		—		3,937
Proceeds from exits of investments	(3,937)		—		—		(3,937)
Unrealized losses on marketable equity securities	—		(1,735)		—		(1,735)
Loss attributable to equity method investments	—		—		(7,265)		(7,265)
Dividends received	—		—		(2,873)		(2,873)
Foreign currency translation adjustments	—		—		2,853		2,853
Carrying value at the end of the period	$	68,748	$	12,423	$	65,366	$	146,537

(1)Includes additions from purchases and an equity method investment acquired and measured at fair value via our acquisition of MEDIFOX DAN. Refer to Note 17 herein.

Net unrealized gains and losses recognized in the years ended June 30, 2024, 2023 and 2022 for equity investments in non-marketable and marketable securities still held as of those respective dates were a loss of $4.0 million, a gain of $6.0 million, and a loss of $16.2 million, respectively.